Redcare Pharmacy stock falls 10.7% as Q3 growth stays Rx-led
Published on 10/31/2026 at 10:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRx Growth Drives Redcare Results
- Third-quarter revenue rose 18 percent to 847 million euros, led by prescription sales.
- Adjusted EBITDA increased 68 percent to 28.7 million euros, while net income reached 1 million euros.
- Redcare kept its upgraded 2026 revenue, German prescription and adjusted EBITDA margin targets.
Redcare Pharmacy reported stronger third-quarter results on Thursday, October 29, as German prescription sales continued to lead growth. Reuters, published through Investing.com, reported that group revenue increased 18 percent year over year to 847 million euros.
Prescription revenue rose 31 percent to 358 million euros. Germany was the main growth engine, with prescription revenue up 56 percent to 197 million euros. Non-prescription revenue increased 9 percent to 489 million euros, slightly below the company-compiled forecast cited by Reuters.
Profitability Improves Despite Mixed Trends
Adjusted EBITDA increased 68 percent to 28.7 million euros, lifting the margin to 3.4 percent from 2.4 percent a year earlier. Net income reached 1 million euros, marking a second consecutive quarterly profit. Free cash flow was 15 million euros.
The DACH region generated adjusted EBITDA of 29 million euros, compared with 18 million euros in the prior-year quarter. The international business remained at negative adjusted EBITDA of 1 million euros. Redcare said its active customer base reached 15.2 million, an increase of 0.5 million from the second quarter.
2026 Targets Remain Unchanged
Redcare confirmed its upgraded 2026 targets: total revenue growth of 16 to 18 percent, non-prescription growth of 10 to 12 percent, German prescription revenue of 730 million to 760 million euros and an adjusted EBITDA margin of 2.5 to 3.0 percent. The company also said first-nine-month revenue rose 19 percent to 2.55 billion euros, with adjusted EBITDA of 73 million euros.
Redcare Pharmacy stock traded at 69.83 euros on Lang & Schwarz at 10:33 Berlin time on Saturday, October 31, 2026, 0.33 percent above the Xetra close of Friday, October 30. The Xetra close was 10.65 percent below the close of Friday, October 23, based on the weekly comparison. The weekly decline puts the earnings progress against a substantially weaker share-price trend.
Investors can follow the real-time quote of Redcare Pharmacy stock.
The AEX provides the broader Dutch equity-market context for the week.
More news and analyses on Redcare Pharmacy stock.
Redcare Pharmacy at a Glance
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- Xetra symbol: RDC.DE
- Lang & Schwarz quote: 69.83 euros on Saturday, October 31, 2026, at 10:33 Berlin time
- Change against Xetra: 0.33 percent above the Friday, October 30 close
- Weekly Xetra performance: 10.65 percent lower than the Friday, October 23 close
